Results from a recent placebo-controlled trial suggest liraglutide, a glucagon-like peptide-1 analogue approved to treat type 2 diabetes, can help shed body weight and improve glycemic control among people who were very overweight or obese—but not diabetic. The trial, consisting of 3731 participants, also found that participants who had taken liraglutide had a significantly lower incidence of prediabetes after 56 weeks and developed type 2 diabetes at a significantly lower rate compared with participants taking placebo (Pi-Sunyer X et al. N Engl J Med. 2015;373[1]:11-22).